|drug1985||MetaNeb® System Wiki||0.71|
|drug3808||human monoclonal antibody DZIF-10c (Group 1A-2D) Wiki||0.50|
|drug2452||Placebo (NaCl 0.9%) (Group 2D) Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There are 2 clinical trials
Oslo University Hospital has initiated an observational study on hospitalised patients with confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2).
Description: Fatal outcome from COVID-19Measure: Death Time: From date of randomization until the date of death from any cause assessed up to 3 months.
Description: Resolved infectionMeasure: Recovery from COVID-19 Time: From date of randomization until the date of recovery from COVID-19 symptoms assessed up to 3 months.
Description: Percentage of patients requiring intensive care admission or ventilationMeasure: Progression to ICU care or ventilation Time: 30 days
Description: The change in(clearance of) viral RNA measured by polymerase chain reaction assay (PCR) test at days 1, 3, 8,14 and 90 daysMeasure: Clearance of SARS-CoV-2 from respiratory specimen Time: The number of calendar days from date of PCR positive test (counted as 1 day) in respiratory specimen until date of such test first become negative in the respiratory specimen assessed up to 3 months
Description: Cell-mediated and humoral immunityMeasure: Immune response to COVID-19 Time: From date of randomization until the date of clinical follow-up assessed up to 3 months.
Follow-up of patients with a borderline PCR result. Data of patients that were re-tested within 96 hours after receiving a borderline COVID-19 PCR result are reviewed. This is a retrospective study.
Data processed on December 13, 2020.